Jiangsu Nhwa Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Jiangsu Nhwa Pharmaceutical has been growing earnings at an average annual rate of 12.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.6% per year. Jiangsu Nhwa Pharmaceutical's return on equity is 16.1%, and it has net margins of 20.6%.
Key information
12.1%
Earnings growth rate
12.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 5.6% |
| Return on equity | 16.1% |
| Net Margin | 20.6% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Jiangsu Nhwa Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 5,220 | 1,075 | 1,979 | 583 |
| 31 Dec 23 | 5,042 | 1,037 | 1,959 | 549 |
| 30 Sep 23 | 4,834 | 1,044 | 1,885 | 548 |
| 30 Jun 23 | 4,698 | 998 | 1,943 | 501 |
| 31 Mar 23 | 4,485 | 939 | 1,910 | 463 |
| 01 Jan 23 | 4,299 | 901 | 1,849 | 454 |
| 30 Sep 22 | 4,164 | 867 | 1,847 | 408 |
| 30 Jun 22 | 4,072 | 834 | 1,810 | 387 |
| 31 Mar 22 | 4,024 | 819 | 1,743 | 385 |
| 01 Jan 22 | 3,936 | 798 | 1,750 | 352 |
| 30 Sep 21 | 3,879 | 830 | 1,638 | 308 |
| 30 Jun 21 | 3,744 | 787 | 1,587 | 301 |
| 31 Mar 21 | 3,528 | 759 | 1,516 | 277 |
| 31 Dec 20 | 3,361 | 729 | 1,445 | 246 |
| 30 Sep 20 | 3,326 | 714 | 1,435 | 236 |
| 30 Jun 20 | 3,534 | 694 | 1,498 | 214 |
| 31 Mar 20 | 3,837 | 675 | 1,622 | 185 |
| 31 Dec 19 | 4,149 | 663 | 1,664 | 189 |
| 30 Sep 19 | 4,167 | 623 | 1,608 | 182 |
| 30 Jun 19 | 4,090 | 585 | 1,512 | 181 |
| 31 Mar 19 | 3,981 | 549 | 1,421 | 178 |
| 31 Dec 18 | 3,858 | 525 | 1,350 | 172 |
| 30 Sep 18 | 3,764 | 472 | 1,173 | 149 |
| 30 Jun 18 | 3,581 | 447 | 1,077 | 179 |
| 31 Mar 18 | 3,482 | 411 | 1,082 | 146 |
| 31 Dec 17 | 3,394 | 395 | 1,066 | 111 |
| 30 Sep 17 | 3,274 | 400 | 1,121 | 79 |
| 30 Jun 17 | 3,181 | 347 | 1,164 | 0 |
| 31 Mar 17 | 3,097 | 325 | 1,085 | 0 |
| 31 Dec 16 | 3,018 | 310 | 1,005 | 0 |
| 30 Sep 16 | 3,004 | 297 | 963 | 0 |
| 30 Jun 16 | 2,937 | 284 | 880 | 0 |
| 31 Mar 16 | 2,851 | 269 | 856 | 0 |
| 31 Dec 15 | 2,767 | 258 | 817 | 0 |
| 30 Sep 15 | 2,694 | 257 | 760 | 0 |
| 30 Jun 15 | 2,628 | 246 | 745 | 0 |
| 31 Mar 15 | 2,566 | 235 | 718 | 0 |
| 31 Dec 14 | 2,501 | 223 | 692 | 0 |
| 30 Sep 14 | 2,418 | 213 | 676 | 0 |
| 30 Jun 14 | 2,375 | 201 | 675 | 0 |
| 31 Mar 14 | 2,310 | 186 | 677 | 0 |
| 31 Dec 13 | 2,236 | 176 | 659 | 0 |
| 30 Sep 13 | 2,156 | 169 | 626 | 0 |
| 30 Jun 13 | 2,097 | 162 | 608 | 0 |
Quality Earnings: 002262 has high quality earnings.
Growing Profit Margin: 002262's current net profit margins (20.6%) are lower than last year (20.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002262's earnings have grown by 12.1% per year over the past 5 years.
Accelerating Growth: 002262's earnings growth over the past year (14.4%) exceeds its 5-year average (12.1% per year).
Earnings vs Industry: 002262 earnings growth over the past year (14.4%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 002262's Return on Equity (16.1%) is considered low.